Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 2,658 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Continuous infusion Clear all
Recruiting Phase 2 Interventional

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

NCT04683679
View directory record Official record
Conditions
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Interventions
Pembrolizumab, Olaparib, Radiation
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Terminated Not applicable Interventional

Early Ambulation After Adductor Canal Block for Total Knee Arthroplasty

NCT01459861
View directory record Official record
Conditions
Pain, Osteoarthritis
Interventions
Canal Block and Capsular Injection, Femoral Nerve Block with Tibial Nerve Block
Procedure
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

Automated Insulin Delivery for Inpatients With Dysglycemia

NCT06418880
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
AID system with Remote Real-Time CGM, Standard of Care Insulin Therapy + CGM
Device · Combination Product
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Stanford, California • Atlanta, Georgia • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

NCT00854646
View directory record Official record
Conditions
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC

NCT01366820
View directory record Official record
Conditions
Brain Injuries
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
16 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Colton, California • Sacramento, California • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 20, 2026, 5:31 PM EDT
Not yet recruiting Phase 1 Interventional

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

NCT07715903
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm
Interventions
Carfilzomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Terminated Phase 4 Interventional Results available

Repeated Amiodarone Dosing In Cardiac surgicaL Procedures

NCT05004077
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
AMIODARONE
Drug
Lead sponsor
Kevin W Hatton, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Early Phase 1 Interventional

Effects Zulresso on Postpartum Psychosis

NCT05314153
View directory record Official record
Conditions
Postpartum Psychosis
Interventions
Brexanolone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Terminated Phase 3 Interventional Results available

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NCT05493501
View directory record Official record
Conditions
NSCLC
Interventions
Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Gemcitabine
Drug
Lead sponsor
EQRx International, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Springdale, Arkansas • Hollywood, Florida • Pembroke Pines, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

NCT03883919
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions
5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 20, 2026, 5:31 PM EDT
Withdrawn Phase 4 Interventional

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

NCT05494593
View directory record Official record
Conditions
Mucopolysaccharidosis (MPS), Hunter Syndrome
Interventions
ELAPRASE, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)
Drug
Lead sponsor
Takeda
Industry
Eligibility
Up to 6 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Oakland, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting Phase 2 Interventional

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

NCT02605421
View directory record Official record
Conditions
Neuroblastoma
Interventions
Thiotepa, Cyclophosphamide, Melphalan, Etoposide, Carboplatin, Autologous Stem Cell Infusion, Granulocyte colony stimulating factor
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

NCT01028495
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
RX-0201 plus Gemcitabine
Drug
Lead sponsor
Rexahn Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Jacksonville, Florida • Skokie, Illinois • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

NCT00246571
View directory record Official record
Conditions
Breast Neoplasms
Interventions
SU011248, Chemotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
77
States / cities
Corona, California • Fullerton, California • Glendora, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma

NCT01660711
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
5 Fluorouracil, Leucovorin, Irinotecan, Oxaliplatin
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Tranexamic Acid Dosing in Adult Spinal Deformity Surgery

NCT02053363
View directory record Official record
Conditions
Adult Spinal Deformity
Interventions
Tranexamic Acid (Cyklokapron)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

NCT06532032
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Docetaxel
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Irvine, California • Los Alamitos, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

NCT03783936
View directory record Official record
Conditions
Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
Interventions
Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
Drug
Lead sponsor
Ashwin Somasundaram
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 20, 2026, 5:31 PM EDT
Withdrawn Phase 3 Interventional

Intravenous Acetaminophen as Adjuvant Therapy for Pain Control in Geriatric Hip Fracture Patients

NCT01520298
View directory record Official record
Conditions
Pain, Hip Fracture
Interventions
Placebo, Acetaminophen IV
Drug
Lead sponsor
Lancaster General Hospital
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

NCT01290471
View directory record Official record
Conditions
Advanced Solid Malignant Tumors, Advanced Ovarian Cancer
Interventions
U3-1565
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Detroit, Michigan • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 20, 2026, 5:31 PM EDT
Withdrawn Phase 2 Interventional

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

NCT06180863
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
oral azacitidine (CC-486)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

NCT01471444
View directory record Official record
Conditions
Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection
Interventions
Fludarabine, Clofarabine, Busulfan, Thymoglobulin, Stem Cell Infusion, Tacrolimus, Methotrexate
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting Not applicable Interventional

Analgesia-First Sedation in Trauma Patients

NCT05751863
View directory record Official record
Conditions
Mechanical Ventilation, Respiratory Failure
Interventions
Analgesia First Sedation Strategy for Mechanically Ventilated (MV) Trauma Subjects, Protocol Directed Sedation and Daily Sedation Interruption
Other
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

NCT01440088
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
TH-302 in Combination with Doxorubicin, Doxorubicin
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
15 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
44
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 20, 2026, 5:31 PM EDT